ZAI LAB LIMITED Treasury Stock, Value
ZAI LAB LIMITED (ZLAB) had Treasury Stock, Value of $4.35 million as of 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:TreasuryStockValue · last filed 2022-05-10
- 2022-03-31: Treasury Stock, Value $4.35M.
- 2021-12-31: Treasury Stock, Value $4.28M.
- 2021-09-30: Treasury Stock, Value $3.53M.
- 2021-06-30: Treasury Stock, Value $924.00K.
| Period end | Treasury Stock, Value |
|---|---|
| 2022-03-31 | $4.35M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.28M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $3.53M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $924.00K 10-Q · filed 2021-08-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |